Clinical trials: Mucosal Melanoma
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma.
- Conditions
- Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
- Trial name
- NCT03698019
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 815 sites in United States
- Volunteers
- 313 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
This randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physician/patient choice of either high-dose recombinant interferon alfa-2B or ipilimumab, in treating patients with…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma
- Trial name
- NCT02506153
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 576 sites in United States, Canada and 1 more
- Volunteers
- 1,301 people
- Sponsor
- National Cancer Institute (NCI)
Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma
Dinaciclib in Treating Patients With Stage IV Melanoma
This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma, Lentigo Maligna Melanoma, Low-CSD Melanoma
- Trial name
- NCT00937937
- Testing
- Dinaciclib
- Where
- 190 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
This randomized phase III trial studies sargramostim or vaccine therapy alone to see how well they work compared to sargramostim and vaccine therapy together in preventing disease recurrence in patients with melanoma that has…
- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension
- Trial name
- NCT01989572
- Testing
- Laboratory Biomarker Analysis, Sargramostim, Tyrosinase Peptide
- Where
- 148 sites in United States
- Volunteers
- 815 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
This pilot trial studies the side effects of giving pembrolizumab together with stereotactic radiosurgery to treat patients with melanoma or non-small cell lung cancer that has spread to the brain.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma
- Trial name
- NCT02858869
- Testing
- Pembrolizumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
This phase II trial studies how well ipilimumab with or without nivolumab work in treating patients with melanoma that is stage IV or stage III and cannot be removed by surgery.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT03033576
- Testing
- Ipilimumab, Nivolumab
- Where
- 638 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous Melanoma, Mucosal Melanoma
Neoadjuvant and Adjuvant Checkpoint Blockade
This randomized phase II trial studies how well nivolumab with or without ipilimumab or relatlimab before surgery works in treating patients with stage IIIB-IV melanoma that can be removed by surgery.
- Conditions
- Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7
- Trial name
- NCT02519322
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Acral Lentiginous Melanoma, Mucosal Melanoma
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Participants with advanced or metastatic mucosal melanoma (cohort A) and acral lentiginous melanoma (cohort B) eligible for treatment with nivolumab in combination with ipilimumab followed by nivolumab therapy will submit tissue…
- Trial name
- NCT02978443
- Testing
- Nivolumab, Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Georgetown University
Melanoma, Metastatic Melanoma
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
The purpose of this study is to learn what effects (good and bad) an experimental vaccine (LPV7) plus tetanus peptide and other substances called polyICLC, resiquimod, and Montanide ISA-51 have on you and your melanoma.
- Conditions
- Melanoma, Metastatic Melanoma, Mucosal Melanoma
- Trial name
- MEL60 (NCT02126579)
- Testing
- Peptide Vaccine (LPV7) + Tetanus peptide, PolyICLC, Resiquimod
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Craig L Slingluff, Jr
Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
This study will evaluate the safety and tolerability of IL-2 when given in combination with pembrolizumab to patients with advanced melanoma. Aldesleukin may stimulate white blood cells to melanoma cells.
- Conditions
- Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma
- Trial name
- NCT02748564
- Testing
- Aldesleukin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rutgers, The State University of New Jersey
Cutaneous Melanoma, Melanoma
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma.
- Conditions
- Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT02129075
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma, Mucosal Melanoma
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well nab-paclitaxel and bevacizumab or ipilimumab works as first-line therapy in treating patients with stage IV melanoma that cannot be removed by surgery.
- Conditions
- Metastatic Melanoma, Mucosal Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
- Trial name
- NCT02158520
- Testing
- Bevacizumab, Ipilimumab, Laboratory Biomarker Analysis
- Where
- 13 sites in United States
- Volunteers
- 24 people
- Sponsor
- Academic and Community Cancer Research United
Mucosal Lentiginous Melanoma, Acral Melanoma
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Given the poor prognosis and limited treatment options available for patients with mucosal or acral/lentiginous melanomas who develop metastatic disease, genetic discoveries of KIT mutations in these cancers present the need to…
- Conditions
- Mucosal Lentiginous Melanoma, Acral Melanoma, Melanoma
- Trial name
- NCT00788775
- Testing
- Nilotinib
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Mucosal Melanoma, Recurrent Melanoma
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma.
- Conditions
- Mucosal Melanoma, Recurrent Melanoma, Recurrent Uveal Melanoma, Stage IIIA Skin Melanoma
- Trial name
- NCT01961115
- Testing
- Epacadostat, MELITAC 12.1 Peptide Vaccine
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Center
Mucosal Melanoma, Acral/Lentiginous Melanoma
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
The purpose of this study is to evaluate how effective imatinib (Gleevec) is in treating acral/lentiginous and mucosal melanoma which has spread to other parts of the body in patients who's disease carries a c-kit mutation.
- Conditions
- Mucosal Melanoma, Acral/Lentiginous Melanoma, Chronically Sun Damaged Melanomas
- Trial name
- BUS255 (NCT00424515)
- Testing
- Imatinib
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Mucosal Lentiginous Melanoma, Acral Lentiginous Malignant Melanoma
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
The purpose of this study is to evaluate how effective Sunitinib works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region.
- Trial name
- NCT00577382
- Testing
- Sunitinib
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Dana-Farber Cancer Institute
Mucosal Melanoma, Recurrent Melanoma
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
This randomized phase III trial studies carboplatin, paclitaxel, and sorafenib tosylate to see how well they work compared to carboplatin and paclitaxel in treating patients with stage III or stage IV melanoma that cannot be…
- Conditions
- Mucosal Melanoma, Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma
- Trial name
- NCT00110019
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 219 sites in United States, Australia
- Volunteers
- 823 people
- Sponsor
- National Cancer Institute (NCI)
Mucosal Melanoma, Recurrent Melanoma
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
The purpose of this study is to find out how often two investigational drugs that are given together will shrink the patient's tumor and how well they will prolong the time it takes their tumor to grow.
- Conditions
- Mucosal Melanoma, Recurrent Melanoma, Stage IV Melanoma
- Trial name
- NCT01166126
- Testing
- temsirolimus, selumetinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)